Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.
Piccolo, Raffaele; Di Gioia, Giuseppe; Niglio, Tullio; D'Anna, Carolina; De Rosa, Roberta; Strisciuglio, Teresa; Bevilacqua, Michele; Piscione, Federico; Cirillo, Plinio; Galasso, Gennaro.
; 65(2): 130-6, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23221279
Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.
Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.
Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals.
Role of phenotypic and genetic testing in managing clopidogrel therapy.
Significant Discovery of Tetrahydrothieno[3,2-c]pyridine-2-carboxamide Analogs as Potent P2Y12 Receptor Antagonists.
The future of P2Y12 receptor antagonists.
Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.
Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
Neue Antiaggregantien - klinische Aspekte.